Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 16, 2007

Biomarker Discovery and Development Focus of BG Medicine and Applied Biosystems Collaboration

  • BG Medicine and Applied Biosystems entered into a collaboration agreement in which they will work together to enhance biomarker discovery and development.

    Under the terms of the agreement, BG Medicine will integrate life science technology from Applied Biosystems into its proteomic and metabolomic systems pharmacology workflows and begin to explore applications for Applied Biosystems’ genomic tools. The technology will be employed in several programs at BG Medicine over the next two years.

    As part of this collaboration, Applied Biosystems is expected to be able to evaluate how its technology fits into emerging high-throughput platforms and how it supports the evolving requirements of customers in this field.

    “With the rapid emergence of molecular medicine and biomarker-guided drug development initiatives, there is an explosive demand for biomarker discovery and validation research as well as the platforms that will deliver these biomarkers to the market,” said Pieter Muntendam, M.D., president and CEO of BG Medicine. “This broad collaboration with Applied Biosystems should allow us to jointly make important contributions to this new medical and drug development research.”   

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »